ADAM12: A novel first-trimester maternal serum marker for Down syndrome

Prenatal Diagnosis

Volumn 23, Issue 13, 2003, Pages 1086-1091

  Laigaard, Jennie ^a,b,c   Sørensen, Tina ^b   Fröhlich, Camilla ^a   Pedersen, Bent Nørgaard ^b   Christiansen, Michael ^b   Schiøtt, Kirsten ^d   Uldbjerg, Niels ^d   Albrechtsen, Reidar ^a   Clausen, Helle V ^c   Ottesen, Bent ^a,c   Wewer, Ulla M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ADAM12; Down syndrome; IGFBP 3 protease; IGFBP 5 protease; PAPP A; Prenatal diagnosis

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 12; BIOLOGICAL MARKER; DISINTEGRIN; METALLOPROTEINASE; PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DISEASE MARKER; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FETUS GROWTH; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MONTE CARLO METHOD; PREGNANCY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; SCREENING TEST;

ADAM PROTEINS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DISINTEGRINS; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MATERNAL AGE; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 9144261850     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.762     Document Type: Article

References (26)

1. Bang P, Fielder PJ. 1997. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology 138: 3912-3917.
2. Blat C, Villaudy J, Binoux M. 1994. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J Clin Invest 93: 2286-2290.
3. Cuckle HS, van Lith JM. 1999. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 19: 505-512.
4. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
5. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. 1998. A novel secreted form of human ADAM12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 273: 157-166.
6. Guidice LC, Farrel EM, Pham H, Lamson G, Rosenfeld RG. 1990. Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 71: 806-816.
7. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. 1990. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 71: 797-805.
8. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. 1999. Cysteine-rich domain of human ADAM12 (meltrin α) supports tumor cell adhesion. Am J Pathol 154: 1489-1501.
9. Irwin CJ, Suen L, Cheng B, et al. 2000. Human placental trophoblasts secrete a disintegrin metalloprotease very similar to the insulin-like growth factor binding protein-3 protease in human pregnancy serum. Endocrinology 141: 666-674.
10. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34.
11. Kawaguchi N, Xu X, Tajima R, et al. 2002. ADAM12 protease induces adipogenesis in transgenic mice. Am J Pathol 160: 1895-1903.
12. Kronqvist P, Kawaguchi N, Albrechtsen R, et al. 2002. ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice. Am J Pathol 161: 1535-1540.
13. Langford KS, Nicolaides KH, Jones J, Abbas AA, McGregor AM, Miell JP. 1995. Serum insulin-like growth factor binding protein-3 (IGFBP-3) levels and IGFBP-3 protease activity in normal, abnormal and multiple human pregnancy. J Clin Endocrinol Metab 80: 21-27.
14. Larsen SO, Christiansen M, Norgaard-Pedersen B. 1998. Calculation of roc curves in multidimensional likelihood ratio based screening with Down's syndrome as a special case. J Med Screen 5: 57-62.
15. Laursen LS, Overgaard MT, Soe R, et al. 2001. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP-5) independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett 504: 36-40.
16. Loechel F, Gilpin BJ, Engvall E, Albrechtsen R, Wewer UM. 1998. Human ADAM12 (meltrin α) is an active metalloprotease. J Biol Chem 273: 16 993-16 997.
17. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. 2000. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278: 511-515.
18. Morssink LP, Kornman LH, Hallahan TW, et al. 1998. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 18: 147-152.
19. Powel-Braxton L, Hollingshead P, Warburton C, et al. 1993. IGF-I is required for normal embryonic growth in mice. Genes Dev 7: 2609-2617.
20. Primakoff P, Myles DG. 2000. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 16: 83-87.
21. Seals DF, Courtneidge SA. 2003. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30.
22. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. 2000. ADAM12, a disintegrin and metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 275: 18 574-18 580.
23. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. 2002. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 87: 1762-1767.
24. van der Veen J, Beekhuis JR, Cornel MC, Mantingh A, de Walle HE, de Wolf BT. 1997. A demographic approach to the assessment of Down syndrome screening performance. Prenat Diagn 17: 717-724.
25. Wald NJ, Hackshaw AK. 2000. Advances in antenatal screening for Down syndrome. Bailliereres Best Pract Res Clin Obstet Gynaecol 14: 563-580.
26. Wolfsberg TG, Primakoff P, Myles DG, White JM. 1995. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 131: 275-278.